Chanda Sanjay
SEC insider (Form 3/4/5 filer). CIK 0001571820. Chief Development Officer at AN2 Therapeutics, Inc. (ANTX). 11 reported Form 4/5 transactions since Sep 2024; latest on Mar 19, 2026. Located in MENLO PARK, CA.
Companies Chanda Sanjay has filed insider reports for
- AN2 Therapeutics, Inc. (ANTX): Officer, Chief Development Officer
Chanda Sanjay
CIK: 0001571820
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AN2 Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
41.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
66K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
66K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
58K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
58K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
41.7K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirect38K shares- - Jan 6, 2026ANTX
AN2 Therapeutics, Inc.
SaleDirect6K shares at avg. $1.01$6K - Jan 5, 2026ANTX
AN2 Therapeutics, Inc.
SaleDirect3.3K shares at avg. $1.00$3K - Feb 26, 2025ANTX
AN2 Therapeutics, Inc.
AwardDirect50.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 41,665 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 66,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 66,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 57,950 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 57,950 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 41,665 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award | 38,000 | - | $0 | Direct |
| Jan 6, 2026 | ANTX AN2 Therapeutics, Inc. | Sale | 5,956 | $1.01 | $6,027 | Direct |
| Jan 5, 2026 | ANTX AN2 Therapeutics, Inc. | Sale | 3,295 | $1.00 | $3,305 | Direct |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | Award | 50,250 | - | - | Direct |
1-10 of 11 transactions